{"id":"ritonavir-boosted-atazanavir-2-nrtis","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that blocks the HIV protease enzyme, preventing the maturation of infectious viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir concentrations and allowing for lower, more convenient dosing. The two nucleoside reverse transcriptase inhibitors (NRTIs) work synergistically by blocking reverse transcriptase, the enzyme HIV uses to convert its RNA genome into DNA.","oneSentence":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:18.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT01691794","phase":"PHASE4","title":"Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11-30","conditions":"HIV, Pediatric","enrollment":108},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01307488","phase":"PHASE4","title":"Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-09","conditions":"HIV Infection","enrollment":286},{"nctId":"NCT01656109","phase":"PHASE2","title":"Atazavanir/Ritonavir-based HAART in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-07","conditions":"HIV","enrollment":20},{"nctId":"NCT00896051","phase":"PHASE2","title":"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2009-08","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":50},{"nctId":"NCT00225017","phase":"PHASE3","title":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-06","conditions":"HIV Infection, Hyperlipidemia","enrollment":50},{"nctId":"NCT00135356","phase":"PHASE4","title":"Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"HIV-Associated Lipodystrophy Syndrome","enrollment":219},{"nctId":"NCT00135395","phase":"PHASE3","title":"A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00207142","phase":"PHASE4","title":"Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"HIV Infections","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ritonavir boosted Atazanavir + 2 NRTIs","genericName":"Ritonavir boosted Atazanavir + 2 NRTIs","companyName":"Fundacion SEIMC-GESIDA","companyId":"fundacion-seimc-gesida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}